BidaskClub upgraded shares of CryoPort (NASDAQ:CYRX) from a buy rating to a strong-buy rating in a research note released on Wednesday morning.
Several other research analysts have also issued reports on the stock. Roth Capital initiated coverage on shares of CryoPort in a research report on Thursday, November 30th. They issued a buy rating and a $12.50 price target for the company. Needham & Company LLC reissued a buy rating and issued a $11.00 price target (up previously from $10.00) on shares of CryoPort in a research report on Thursday, March 8th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $33.70.
CYRX stock opened at $9.63 on Wednesday. CryoPort has a 52-week low of $1.96 and a 52-week high of $10.40. The stock has a market cap of $273.13, a PE ratio of -27.51 and a beta of 0.71.
In related news, CEO Jerrell Shelton sold 29,257 shares of the stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $9.83, for a total value of $287,596.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 9.00% of the company’s stock.
A number of institutional investors have recently modified their holdings of the business. Pier Capital LLC bought a new stake in CryoPort during the fourth quarter worth about $2,916,000. Millennium Management LLC grew its stake in CryoPort by 71.5% during the fourth quarter. Millennium Management LLC now owns 142,331 shares of the consumer goods maker’s stock worth $1,223,000 after buying an additional 59,331 shares during the last quarter. Goldman Sachs Group Inc. bought a new stake in CryoPort during the fourth quarter worth about $155,000. BlueCrest Capital Management Ltd bought a new stake in CryoPort during the fourth quarter worth about $432,000. Finally, Allianz Asset Management GmbH grew its stake in CryoPort by 240.5% during the fourth quarter. Allianz Asset Management GmbH now owns 387,099 shares of the consumer goods maker’s stock worth $3,325,000 after buying an additional 273,426 shares during the last quarter. 23.71% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This report was posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3298029/bidaskclub-upgrades-cryoport-cyrx-to-strong-buy.html.
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.